Alzamend Neuro, Inc. (NASDAQ:ALZN) (“Alzamend“), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s“), bipolar disorder (“BD“), major depressive disorder (“MDD“) and post-traumatic stress disorder (“PTSD“), announced today that the Nasdaq Hearings Panel (“Panel“) granted Alzamend’s request to continue its listing on The Nasdaq Capital Market (“Nasdaq“), subject to Alzamend demonstrating compliance, on or before September 23, 2024, with Listing Rule 5550(b)(1), which requires stockholder equity of at least $2.5 million (the “Stockholder Equity Rule“), and satisfying all applicable requirements for continued listing on Nasdaq.
Nasdaq Hearings Panel Granted Alzamend’s Request To Continue Its Listing, Subject To Alzamend Demonstrating Compliance, On Or Before September 23, 2024
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major
Related Posts
Barclays Maintains Overweight on Solid Biosciences, Raises Price Target to $8
Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $2 to $8.
GameStop Implementing A Bitcoin Treasury Strategy Would Be ‘A Brilliant Move’ And Could Push The Stock To $1,000, Says Bitcoiner
Bitcoin (CRYPTO: BTC) influencer Max Keiser suggested a strategy for GameStop (NYSE:GME) that would, in his opinion, push the stock price to $1,000.
Why Baidu Stock Is Trading Higher
Baidu Inc (NASDAQ: BIDU) shares are trading higher by 4.5% to $149.24 Friday morning. Shares of Chinese stocks are trading higher after China cut the minimum down payment on mortgages as part of stimulus measures.